| Name | Title | Contact Details |
|---|---|---|
Jerry Gibson |
Chief Executive Officer | Profile |
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Paragon Intellectual Properties is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
WIDTHMAN USA is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Apollo is a American Fork, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Globus Medical is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.Globus Medical, Inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. Founded in 2003, Globus` single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. Globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders